Avoiding surgery after precision therapy for gastrointestinal cancers
Part of Cancer, Digestive system clinical trials.
This study looks at whether people with gastrointestinal cancers who respond well to targeted or immunotherapy can safely avoid surgery and keep their organs. It aims to see if close monitoring and follow-up instead of surgery is a good option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have a gastrointestinal cancer such as stomach, esophageal, or colorectal cancer.
- Your tumor has a specific marker (like MSI-H, HER2, or another genetic change) that helps guide targeted treatment.
- After receiving targeted therapy or immunotherapy, your tumor has shrunk or disappeared significantly.
- A team of doctors has reviewed your case and thinks that avoiding surgery or preserving your organ might be possible.
- You are willing and able to come back for regular check-ups as required.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether people with certain types of colorectal or other gastrointestinal cancers can avoid or delay surgery and instead be monitored closely (watch-and-wait) after receiving immunotherapy. It aims to see if this approach can keep the cancer from coming back while improving quality of life.
This trial tests whether skipping chemotherapy after surgery is safe and effective for some patients with gastric cancer. If your tumor responded very well or very poorly to the pre-surgery chemotherapy, you might be able to avoid more chemo.
This trial compares having surgery to remove stomach cancer versus not having surgery in patients whose cancer in the abdominal lining responded well to initial treatment. The goal is to see which approach helps patients live longer and feel better.
This trial tests whether using immune checkpoint inhibitors alone (like checkpoint blockade drugs) can help people with certain gastric or colon cancers avoid surgery. It's for patients whose tumors have a specific genetic feature called dMMR/MSI-H and haven't spread to other parts of the body.
This trial tests whether giving a combination of two immunotherapy drugs before surgery can help shrink stomach cancer and reduce the chance of it coming back. It is for people whose tumors have a specific genetic feature called MSI-H or dMMR, which often responds well to immunotherapy.
This trial tests a minimally invasive surgery for stomach cancer that has spread to lymph nodes near the main blood vessels (para-aortic area). The surgery is done after a combination of chemotherapy and immunotherapy to shrink the tumor. It aims to see if this approach is safe and effective.
Hear when a new Gastrointestinal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.